B
휴젤
145020KOSDAQ기초 의약물질 제조업61.0 / 100
Reference Date: 2026-04-13
Financial Score28.5 / 40
News Sentiment13.5 / 25
Momentum9.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Rose 6.5% over the past month, and news sentiment is positive.
Company InformationBased on 2025 Annual Report
Business Overview
Hujeel develops and manufactures biopharmaceuticals based on Clostridium botulinum type A toxin, and directly handles sales after merging with its subsidiary, Hujel Pharma, in 2018. Its major subsidiary, Acros, focuses on HA filler development and production. Both botulinum toxin and HA fillers have broad applications in medical and cosmetic fields.
Number of Employees
629people
Average Salary
64.7M KRW
Score Calculation Basis
Detailed Financial Score
PER
19.52Industry Average 33.456.5Point
Lower than industry avg (good)
PBR
3.20Industry Average 2.031.0Point
1.6x industry avg (risky)
ROE
16.14Industry Average -4.293.5Point
Well below industry avg
Debt Ratio
0.37Industry Average 6.618.0Point
Half of industry avg (excellent)
Trend 2023~20259.5 / 10 points
Revenue Growth Rate
2.5 / 3
Avg ▲15.3% (2-year basis)
Operating Profit Growth Rate
3.0 / 3
Avg ▲31.0% (2-year basis)
ROE Trend
4.0 / 4
Avg ROE 15.3% (improving, 3yr)
Detailed News Sentiment
18 totalPositive 3Neutral 10Negative 0Average Sentiment Score 55.8
- Neutral
- Neutral
- Neutral
Detailed Momentum
52-week position3.0Point
52w lower range (23%)
Current 255,000Won52-week high 388,00052-week low 214,000
1-month return4.0Point
1m +6.47% (slight rise)
Volume trend2.0Point
Volume decreasing
Detailed Disclosure
9 totalPositive 0Neutral 9Negative 0
- Neutral[기재정정]주식매수선택권부여에관한신고2026-03-31
- Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-31
- Neutral정기주주총회결과2026-03-31
- Neutral사업보고서 (2025.12)2026-03-20
- Neutral감사보고서제출2026-03-19